$1.56
Live
Insights on Icad Inc
Revenue is up for the last 3 quarters, 4.07M → 4.95M (in $), with an average increase of 9.2% per quarter
Netprofit is down for the last 2 quarters, 1.36M → -1.22M (in $), with an average decrease of 189.7% per quarter
In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 19.5%
In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 170.2%
3.17%
Downside
Day's Volatility :7.89%
Upside
4.88%
26.92%
Downside
52 Weeks Volatility :71.28%
Upside
60.71%
Period | Icad Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -27.59% | -1.0% | 0.0% |
6 Months | -1.2% | 9.6% | 0.0% |
1 Year | 28.12% | 11.0% | 0.0% |
3 Years | -90.65% | 18.5% | -22.6% |
Market Capitalization | 38.5M |
Book Value | $1.23 |
Earnings Per Share (EPS) | -0.2 |
PEG Ratio | -0.56 |
Wall Street Target Price | 4.83 |
Profit Margin | -12.77% |
Operating Margin TTM | -29.09% |
Return On Assets TTM | -8.38% |
Return On Equity TTM | -16.02% |
Revenue TTM | 17.9M |
Revenue Per Share TTM | 0.69 |
Quarterly Revenue Growth YOY | -14.299999999999999% |
Gross Profit TTM | 20.1M |
EBITDA | -5.5M |
Diluted Eps TTM | -0.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.23 |
EPS Estimate Next Year | -0.18 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 209.62%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 25.6M | ↓ 8.83% |
Net Income | -9.0M | ↓ 36.75% |
Net Profit Margin | -35.19% | ↑ 15.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.3M | ↑ 22.32% |
Net Income | -13.6M | ↑ 50.28% |
Net Profit Margin | -43.24% | ↓ 8.05% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 29.7M | ↓ 5.24% |
Net Income | -17.6M | ↑ 29.95% |
Net Profit Margin | -59.3% | ↓ 16.06% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 33.6M | ↑ 13.27% |
Net Income | -11.2M | ↓ 36.14% |
Net Profit Margin | -33.43% | ↑ 25.87% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.9M | ↓ 16.93% |
Net Income | -13.7M | ↑ 21.44% |
Net Profit Margin | -48.87% | ↓ 15.44% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 17.3M | ↓ 38.03% |
Net Income | -7.4M | ↓ 45.53% |
Net Profit Margin | -42.96% | ↑ 5.91% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.5M | ↑ 2.09% |
Net Income | -3.1M | ↓ 19.32% |
Net Profit Margin | -47.7% | ↑ 12.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↓ 10.96% |
Net Income | -3.8M | ↑ 22.07% |
Net Profit Margin | -65.39% | ↓ 17.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.9M | ↑ 1.51% |
Net Income | -1.8M | ↓ 53.68% |
Net Profit Margin | -29.84% | ↑ 35.55% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.1M | ↓ 30.55% |
Net Income | -1.4M | ↓ 21.49% |
Net Profit Margin | -33.73% | ↓ 3.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.7M | ↑ 16.4% |
Net Income | 1.4M | ↓ 199.13% |
Net Profit Margin | 28.73% | ↑ 62.46% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.0M | ↑ 4.49% |
Net Income | -1.2M | ↓ 189.72% |
Net Profit Margin | -24.67% | ↓ 53.4% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 31.7M | ↓ 1.23% |
Total Liabilities | 24.8M | ↑ 39.13% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 41.7M | ↑ 31.54% |
Total Liabilities | 36.7M | ↑ 47.65% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 55.6M | ↑ 33.14% |
Total Liabilities | 25.1M | ↓ 31.68% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 62.2M | ↑ 11.89% |
Total Liabilities | 15.7M | ↓ 37.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 51.7M | ↓ 16.86% |
Total Liabilities | 16.8M | ↑ 7.2% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 41.4M | ↓ 19.9% |
Total Liabilities | 8.0M | ↓ 52.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 51.7M | ↓ 6.63% |
Total Liabilities | 16.8M | ↓ 5.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 47.5M | ↓ 8.1% |
Total Liabilities | 15.8M | ↓ 5.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 44.8M | ↓ 5.65% |
Total Liabilities | 14.7M | ↓ 7.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 45.8M | ↑ 2.22% |
Total Liabilities | 14.8M | ↑ 0.92% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 41.4M | ↓ 9.62% |
Total Liabilities | 8.0M | ↓ 45.91% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 40.4M | ↓ 2.47% |
Total Liabilities | 7.9M | ↓ 0.82% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↓ 47.29% |
Investing Cash Flow | -316.0K | ↓ 112.87% |
Financing Cash Flow | 7.0M | ↑ 22.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.1M | ↑ 83.79% |
Investing Cash Flow | -306.0K | ↓ 3.16% |
Financing Cash Flow | 10.5M | ↑ 51.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.0M | ↓ 1.72% |
Investing Cash Flow | -474.0K | ↑ 54.9% |
Financing Cash Flow | 19.3M | ↑ 83.4% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.4M | ↑ 34.69% |
Investing Cash Flow | -587.0K | ↑ 23.84% |
Financing Cash Flow | 17.1M | ↓ 11.59% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.8M | ↑ 35.94% |
Investing Cash Flow | -534.0K | ↓ 9.03% |
Financing Cash Flow | 355.0K | ↓ 97.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.1M | ↑ 18.03% |
Investing Cash Flow | -122.0K | ↑ 22.0% |
Financing Cash Flow | 22.0K | ↓ 86.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.5M | ↓ 51.17% |
Investing Cash Flow | -122.0K | ↑ 0.0% |
Financing Cash Flow | -16.0K | ↓ 172.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -405.0K | ↓ 73.49% |
Investing Cash Flow | -221.0K | ↑ 81.15% |
Financing Cash Flow | 46.0K | ↓ 388.31% |
Sell
Neutral
Buy
Icad Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Icad Inc | 14.69% | -1.2% | 28.12% | -90.65% | -73.03% |
Stryker Corporation | 4.27% | 16.65% | 22.1% | 34.77% | 82.03% |
Boston Scientific Corp. | 4.07% | 37.85% | 46.89% | 79.63% | 93.34% |
Edwards Lifesciences Corp. | 3.26% | 27.0% | 2.23% | -8.36% | 51.45% |
Abbott Laboratories | -2.62% | -2.21% | -0.86% | -5.87% | 32.8% |
Medtronic Plc | 0.44% | 2.96% | -1.92% | -33.69% | -13.02% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Icad Inc | NA | NA | -0.56 | -0.23 | -0.16 | -0.08 | NA | 1.23 |
Stryker Corporation | 38.89 | 38.89 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.5 | 63.5 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 37.45 | 37.45 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 31.83 | 31.83 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 29.48 | 29.48 | 1.52 | 5.2 | 0.07 | 0.04 | 0.03 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Icad Inc | Buy | $38.5M | -73.03% | NA | -12.77% |
Stryker Corporation | Buy | $129.9B | 82.03% | 38.89 | 16.03% |
Boston Scientific Corp. | Buy | $111.1B | 93.34% | 63.5 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | 51.45% | 37.45 | 23.01% |
Abbott Laboratories | Buy | $177.8B | 32.8% | 31.83 | 13.96% |
Medtronic Plc | Buy | $106.7B | -13.02% | 29.48 | 11.36% |
Portolan Capital Management, LLC
Vanguard Group Inc
Arnhold & S. Bleichroeder Advisers, LLC
Renaissance Technologies Corp
BlackRock Inc
Greenwood Capital Associates, LLC
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Organization | Icad Inc |
Employees | 67 |
CEO | Ms. Dana R. Brown |
Industry | Electronic Technology |
A Spac I Acquisition Corp
$1.56
-4.88%
Keyarch Acquisition Corp
$1.56
-4.88%
Connexa Sports Technologies Inc
$1.56
-4.88%
Us Value Etf
$1.56
-4.88%
First Wave Biopharma Inc
$1.56
-4.88%
Global X Msci Next Emerging
$1.56
-4.88%
Fat Projects Acquisition Corp
$1.56
-4.88%
Goal Acquisitions Corp
$1.56
-4.88%
Capital Link Global Fintech
$1.56
-4.88%